The Experts below are selected from a list of 282 Experts worldwide ranked by ideXlab platform
Kohkan Shamsi - One of the best experts on this subject based on the ideXlab platform.
-
spio enhanced 2d tof mr angiography of the Portal Venous System results of an intraindividual comparison
Journal of Magnetic Resonance Imaging, 1997Co-Authors: Peter Reimer, Christian Marx, Ernst J. Rummeny, Markus Müller, Markus G. Lentschig, Thomas Balzer, Karl-heinz Dietl, Udo Sulkowski, Thomas Berns, Kohkan ShamsiAbstract:The purpose of this study was to investigate whether MR angiography (MRA) of the Portal Venous System may be improved by means of superparamagnetic iron oxides (SPIOs) during accumulation phase imaging and to study the underlying contrast mechanisms. MRA of the Portal Venous System was performed on 48 patients before and after intraVenous injection of a new SPIO (Resovist, Schering AG, Berlin, Germany). Resovist, as a predominantly liver parenchymal darkening agent on T2-weighted MR images with uptake into the reticuloendothelial cell System, was administered intraVenously by bolus injection of 8 to 12 micromol Fe/kg body weight. Patients were scanned with breath-hold coronal and axial two-dimensional (2D) time of flight (TOF) MRA (TR = 31.0 msec, TE = 9.8 msec, flip angle (FA) = 50 degrees, and 6.9-second acquisition time per section) sequences. Signal intensity values of liver parenchyma, the Portal Venous System, and background were obtained for quantitative analysis. The clinical relevance of additional plain and contrast-enhanced MRA studies for surgical planning was assessed by independent reading of three readers. Liver signal-to-noise ratio (SNR) significantly decreased following iv injection of Resovist; however, SNR values of the Portal veins or hepatic veins did not change significantly. Visibility of the Portal Venous System improved significantly (tertiary branches visible: pre in 15.2% versus post in 87.0% of patients). Resovist-enhanced 2D-TOF MRA may improve planning of liver resections by better demonstrating the relationship of central liver lesions and vessels on source images. The decrease in liver SNR at a constant vessel SNR after iv injection of Resovist improves MRA of the liver. SPIO-enhanced 2D-TOF MRA scans are superior to plain 2D-TOF MRA studies and may be added for the workup of preoperative patients.
-
SPIO‐enhanced 2D‐TOF MR angiography of the Portal Venous System: Results of an intraindividual comparison
Journal of magnetic resonance imaging : JMRI, 1997Co-Authors: Peter Reimer, Christian Marx, Ernst J. Rummeny, Markus Müller, Markus G. Lentschig, Thomas Balzer, Karl-heinz Dietl, Udo Sulkowski, Thomas Berns, Kohkan ShamsiAbstract:The purpose of this study was to investigate whether MR angiography (MRA) of the Portal Venous System may be improved by means of superparamagnetic iron oxides (SPIOs) during accumulation phase imaging and to study the underlying contrast mechanisms. MRA of the Portal Venous System was performed on 48 patients before and after intraVenous injection of a new SPIO (Resovist, Schering AG, Berlin, Germany). Resovist, as a predominantly liver parenchymal darkening agent on T2-weighted MR images with uptake into the reticuloendothelial cell System, was administered intraVenously by bolus injection of 8 to 12 micromol Fe/kg body weight. Patients were scanned with breath-hold coronal and axial two-dimensional (2D) time of flight (TOF) MRA (TR = 31.0 msec, TE = 9.8 msec, flip angle (FA) = 50 degrees, and 6.9-second acquisition time per section) sequences. Signal intensity values of liver parenchyma, the Portal Venous System, and background were obtained for quantitative analysis. The clinical relevance of additional plain and contrast-enhanced MRA studies for surgical planning was assessed by independent reading of three readers. Liver signal-to-noise ratio (SNR) significantly decreased following iv injection of Resovist; however, SNR values of the Portal veins or hepatic veins did not change significantly. Visibility of the Portal Venous System improved significantly (tertiary branches visible: pre in 15.2% versus post in 87.0% of patients). Resovist-enhanced 2D-TOF MRA may improve planning of liver resections by better demonstrating the relationship of central liver lesions and vessels on source images. The decrease in liver SNR at a constant vessel SNR after iv injection of Resovist improves MRA of the liver. SPIO-enhanced 2D-TOF MRA scans are superior to plain 2D-TOF MRA studies and may be added for the workup of preoperative patients.
Yukio Miki - One of the best experts on this subject based on the ideXlab platform.
-
Splenic Vein Diameter is a Risk Factor for the Portal Venous System Thrombosis After Partial Splenic Artery Embolization
CardioVascular and Interventional Radiology, 2021Co-Authors: Satoyuki Ogawa, Akira Yamamoto, Atsushi Jogo, Mariko M. Nakano, Ken Kageyama, Etsuji Sohgawa, Norifumi Nishida, Toshio Kaminou, Yukio MikiAbstract:Purpose Portal Venous System thrombosis is a complication of partial splenic artery embolization, and pre-treatment risk assessment is thus important. The purpose of this study was to identify the risk factors for Portal Venous System thrombosis after partial splenic artery embolization. Materials and methods We retrospectively analyzed 67 consecutive patients who underwent contrast-enhanced computed tomography before and after first partial splenic artery embolization between July 2007 and October 2018. As risk factors, we investigated age, sex, hematological data, liver function, steroid use, heparin use, and findings from pre- and post-treatment computed tomography. Uni- and multivariate analyses were performed to evaluate the relationship between thrombus appearance or growth and these factors. Values of p
-
splenic vein diameter is a risk factor for the Portal Venous System thrombosis after partial splenic artery embolization
CardioVascular and Interventional Radiology, 2021Co-Authors: Satoyuki Ogawa, Akira Yamamoto, Atsushi Jogo, Mariko M. Nakano, Ken Kageyama, Etsuji Sohgawa, Norifumi Nishida, Toshio Kaminou, Yukio MikiAbstract:PURPOSE Portal Venous System thrombosis is a complication of partial splenic artery embolization, and pre-treatment risk assessment is thus important. The purpose of this study was to identify the risk factors for Portal Venous System thrombosis after partial splenic artery embolization. MATERIALS AND METHODS We retrospectively analyzed 67 consecutive patients who underwent contrast-enhanced computed tomography before and after first partial splenic artery embolization between July 2007 and October 2018. As risk factors, we investigated age, sex, hematological data, liver function, steroid use, heparin use, and findings from pre- and post-treatment computed tomography. Uni- and multivariate analyses were performed to evaluate the relationship between thrombus appearance or growth and these factors. Values of p < 0.05 were considered significant. RESULTS Partial splenic artery embolization was technically successful in all 67 patients. Nine patients showed appearance or growth of thrombus. Univariate analysis showed maximum diameter of the splenic vein before treatment (p = 0.0076), percentage of infarcted spleen (p = 0.017), and volume of infarcted spleen (p = 0.022) as significant risk factors. Multivariate analysis showed significant differences in maximum diameter of the splenic vein before treatment (p = 0.041) and percentage of infarcted spleen (p = 0.023). According to receiver operating characteristic analysis, cutoffs for maximum diameter of the splenic vein and percentage of infarcted spleen for distinguishing the appearance or growth of thrombus were 17 mm and 58.2%. CONCLUSION Large maximum diameter of the splenic vein before partial splenic artery embolization and high percentage of infarcted spleen after partial splenic artery embolization were identified as risk factors for Portal Venous System thrombosis. LEVEL OF EVIDENCE Level 4, Case Series.
Peter Reimer - One of the best experts on this subject based on the ideXlab platform.
-
spio enhanced 2d tof mr angiography of the Portal Venous System results of an intraindividual comparison
Journal of Magnetic Resonance Imaging, 1997Co-Authors: Peter Reimer, Christian Marx, Ernst J. Rummeny, Markus Müller, Markus G. Lentschig, Thomas Balzer, Karl-heinz Dietl, Udo Sulkowski, Thomas Berns, Kohkan ShamsiAbstract:The purpose of this study was to investigate whether MR angiography (MRA) of the Portal Venous System may be improved by means of superparamagnetic iron oxides (SPIOs) during accumulation phase imaging and to study the underlying contrast mechanisms. MRA of the Portal Venous System was performed on 48 patients before and after intraVenous injection of a new SPIO (Resovist, Schering AG, Berlin, Germany). Resovist, as a predominantly liver parenchymal darkening agent on T2-weighted MR images with uptake into the reticuloendothelial cell System, was administered intraVenously by bolus injection of 8 to 12 micromol Fe/kg body weight. Patients were scanned with breath-hold coronal and axial two-dimensional (2D) time of flight (TOF) MRA (TR = 31.0 msec, TE = 9.8 msec, flip angle (FA) = 50 degrees, and 6.9-second acquisition time per section) sequences. Signal intensity values of liver parenchyma, the Portal Venous System, and background were obtained for quantitative analysis. The clinical relevance of additional plain and contrast-enhanced MRA studies for surgical planning was assessed by independent reading of three readers. Liver signal-to-noise ratio (SNR) significantly decreased following iv injection of Resovist; however, SNR values of the Portal veins or hepatic veins did not change significantly. Visibility of the Portal Venous System improved significantly (tertiary branches visible: pre in 15.2% versus post in 87.0% of patients). Resovist-enhanced 2D-TOF MRA may improve planning of liver resections by better demonstrating the relationship of central liver lesions and vessels on source images. The decrease in liver SNR at a constant vessel SNR after iv injection of Resovist improves MRA of the liver. SPIO-enhanced 2D-TOF MRA scans are superior to plain 2D-TOF MRA studies and may be added for the workup of preoperative patients.
-
SPIO‐enhanced 2D‐TOF MR angiography of the Portal Venous System: Results of an intraindividual comparison
Journal of magnetic resonance imaging : JMRI, 1997Co-Authors: Peter Reimer, Christian Marx, Ernst J. Rummeny, Markus Müller, Markus G. Lentschig, Thomas Balzer, Karl-heinz Dietl, Udo Sulkowski, Thomas Berns, Kohkan ShamsiAbstract:The purpose of this study was to investigate whether MR angiography (MRA) of the Portal Venous System may be improved by means of superparamagnetic iron oxides (SPIOs) during accumulation phase imaging and to study the underlying contrast mechanisms. MRA of the Portal Venous System was performed on 48 patients before and after intraVenous injection of a new SPIO (Resovist, Schering AG, Berlin, Germany). Resovist, as a predominantly liver parenchymal darkening agent on T2-weighted MR images with uptake into the reticuloendothelial cell System, was administered intraVenously by bolus injection of 8 to 12 micromol Fe/kg body weight. Patients were scanned with breath-hold coronal and axial two-dimensional (2D) time of flight (TOF) MRA (TR = 31.0 msec, TE = 9.8 msec, flip angle (FA) = 50 degrees, and 6.9-second acquisition time per section) sequences. Signal intensity values of liver parenchyma, the Portal Venous System, and background were obtained for quantitative analysis. The clinical relevance of additional plain and contrast-enhanced MRA studies for surgical planning was assessed by independent reading of three readers. Liver signal-to-noise ratio (SNR) significantly decreased following iv injection of Resovist; however, SNR values of the Portal veins or hepatic veins did not change significantly. Visibility of the Portal Venous System improved significantly (tertiary branches visible: pre in 15.2% versus post in 87.0% of patients). Resovist-enhanced 2D-TOF MRA may improve planning of liver resections by better demonstrating the relationship of central liver lesions and vessels on source images. The decrease in liver SNR at a constant vessel SNR after iv injection of Resovist improves MRA of the liver. SPIO-enhanced 2D-TOF MRA scans are superior to plain 2D-TOF MRA studies and may be added for the workup of preoperative patients.
Satoyuki Ogawa - One of the best experts on this subject based on the ideXlab platform.
-
Splenic Vein Diameter is a Risk Factor for the Portal Venous System Thrombosis After Partial Splenic Artery Embolization
CardioVascular and Interventional Radiology, 2021Co-Authors: Satoyuki Ogawa, Akira Yamamoto, Atsushi Jogo, Mariko M. Nakano, Ken Kageyama, Etsuji Sohgawa, Norifumi Nishida, Toshio Kaminou, Yukio MikiAbstract:Purpose Portal Venous System thrombosis is a complication of partial splenic artery embolization, and pre-treatment risk assessment is thus important. The purpose of this study was to identify the risk factors for Portal Venous System thrombosis after partial splenic artery embolization. Materials and methods We retrospectively analyzed 67 consecutive patients who underwent contrast-enhanced computed tomography before and after first partial splenic artery embolization between July 2007 and October 2018. As risk factors, we investigated age, sex, hematological data, liver function, steroid use, heparin use, and findings from pre- and post-treatment computed tomography. Uni- and multivariate analyses were performed to evaluate the relationship between thrombus appearance or growth and these factors. Values of p
-
splenic vein diameter is a risk factor for the Portal Venous System thrombosis after partial splenic artery embolization
CardioVascular and Interventional Radiology, 2021Co-Authors: Satoyuki Ogawa, Akira Yamamoto, Atsushi Jogo, Mariko M. Nakano, Ken Kageyama, Etsuji Sohgawa, Norifumi Nishida, Toshio Kaminou, Yukio MikiAbstract:PURPOSE Portal Venous System thrombosis is a complication of partial splenic artery embolization, and pre-treatment risk assessment is thus important. The purpose of this study was to identify the risk factors for Portal Venous System thrombosis after partial splenic artery embolization. MATERIALS AND METHODS We retrospectively analyzed 67 consecutive patients who underwent contrast-enhanced computed tomography before and after first partial splenic artery embolization between July 2007 and October 2018. As risk factors, we investigated age, sex, hematological data, liver function, steroid use, heparin use, and findings from pre- and post-treatment computed tomography. Uni- and multivariate analyses were performed to evaluate the relationship between thrombus appearance or growth and these factors. Values of p < 0.05 were considered significant. RESULTS Partial splenic artery embolization was technically successful in all 67 patients. Nine patients showed appearance or growth of thrombus. Univariate analysis showed maximum diameter of the splenic vein before treatment (p = 0.0076), percentage of infarcted spleen (p = 0.017), and volume of infarcted spleen (p = 0.022) as significant risk factors. Multivariate analysis showed significant differences in maximum diameter of the splenic vein before treatment (p = 0.041) and percentage of infarcted spleen (p = 0.023). According to receiver operating characteristic analysis, cutoffs for maximum diameter of the splenic vein and percentage of infarcted spleen for distinguishing the appearance or growth of thrombus were 17 mm and 58.2%. CONCLUSION Large maximum diameter of the splenic vein before partial splenic artery embolization and high percentage of infarcted spleen after partial splenic artery embolization were identified as risk factors for Portal Venous System thrombosis. LEVEL OF EVIDENCE Level 4, Case Series.
Udo Sulkowski - One of the best experts on this subject based on the ideXlab platform.
-
spio enhanced 2d tof mr angiography of the Portal Venous System results of an intraindividual comparison
Journal of Magnetic Resonance Imaging, 1997Co-Authors: Peter Reimer, Christian Marx, Ernst J. Rummeny, Markus Müller, Markus G. Lentschig, Thomas Balzer, Karl-heinz Dietl, Udo Sulkowski, Thomas Berns, Kohkan ShamsiAbstract:The purpose of this study was to investigate whether MR angiography (MRA) of the Portal Venous System may be improved by means of superparamagnetic iron oxides (SPIOs) during accumulation phase imaging and to study the underlying contrast mechanisms. MRA of the Portal Venous System was performed on 48 patients before and after intraVenous injection of a new SPIO (Resovist, Schering AG, Berlin, Germany). Resovist, as a predominantly liver parenchymal darkening agent on T2-weighted MR images with uptake into the reticuloendothelial cell System, was administered intraVenously by bolus injection of 8 to 12 micromol Fe/kg body weight. Patients were scanned with breath-hold coronal and axial two-dimensional (2D) time of flight (TOF) MRA (TR = 31.0 msec, TE = 9.8 msec, flip angle (FA) = 50 degrees, and 6.9-second acquisition time per section) sequences. Signal intensity values of liver parenchyma, the Portal Venous System, and background were obtained for quantitative analysis. The clinical relevance of additional plain and contrast-enhanced MRA studies for surgical planning was assessed by independent reading of three readers. Liver signal-to-noise ratio (SNR) significantly decreased following iv injection of Resovist; however, SNR values of the Portal veins or hepatic veins did not change significantly. Visibility of the Portal Venous System improved significantly (tertiary branches visible: pre in 15.2% versus post in 87.0% of patients). Resovist-enhanced 2D-TOF MRA may improve planning of liver resections by better demonstrating the relationship of central liver lesions and vessels on source images. The decrease in liver SNR at a constant vessel SNR after iv injection of Resovist improves MRA of the liver. SPIO-enhanced 2D-TOF MRA scans are superior to plain 2D-TOF MRA studies and may be added for the workup of preoperative patients.
-
SPIO‐enhanced 2D‐TOF MR angiography of the Portal Venous System: Results of an intraindividual comparison
Journal of magnetic resonance imaging : JMRI, 1997Co-Authors: Peter Reimer, Christian Marx, Ernst J. Rummeny, Markus Müller, Markus G. Lentschig, Thomas Balzer, Karl-heinz Dietl, Udo Sulkowski, Thomas Berns, Kohkan ShamsiAbstract:The purpose of this study was to investigate whether MR angiography (MRA) of the Portal Venous System may be improved by means of superparamagnetic iron oxides (SPIOs) during accumulation phase imaging and to study the underlying contrast mechanisms. MRA of the Portal Venous System was performed on 48 patients before and after intraVenous injection of a new SPIO (Resovist, Schering AG, Berlin, Germany). Resovist, as a predominantly liver parenchymal darkening agent on T2-weighted MR images with uptake into the reticuloendothelial cell System, was administered intraVenously by bolus injection of 8 to 12 micromol Fe/kg body weight. Patients were scanned with breath-hold coronal and axial two-dimensional (2D) time of flight (TOF) MRA (TR = 31.0 msec, TE = 9.8 msec, flip angle (FA) = 50 degrees, and 6.9-second acquisition time per section) sequences. Signal intensity values of liver parenchyma, the Portal Venous System, and background were obtained for quantitative analysis. The clinical relevance of additional plain and contrast-enhanced MRA studies for surgical planning was assessed by independent reading of three readers. Liver signal-to-noise ratio (SNR) significantly decreased following iv injection of Resovist; however, SNR values of the Portal veins or hepatic veins did not change significantly. Visibility of the Portal Venous System improved significantly (tertiary branches visible: pre in 15.2% versus post in 87.0% of patients). Resovist-enhanced 2D-TOF MRA may improve planning of liver resections by better demonstrating the relationship of central liver lesions and vessels on source images. The decrease in liver SNR at a constant vessel SNR after iv injection of Resovist improves MRA of the liver. SPIO-enhanced 2D-TOF MRA scans are superior to plain 2D-TOF MRA studies and may be added for the workup of preoperative patients.